Showing results (1691-1700 of 2,063) with videos related to

Sort By:
Pageof 207
Brachytherapy|June 24, 2019
Influence of transitioning of planning techniques in high-dose-rate brachytherapy monotherapy for clinically localized prostate cancer from two- to three-dimensional planningHideya Yamazaki, Koji Masui, Gen Suzuki, et al.
Brachytherapy|June 26, 2019
Recurrence rates for patients with early-stage breast cancer treated with IOERT at a community hospital per the ASTRO consensus statement for APBIVenita L Williams, Tanuja Bhandari, Lillian J Chen, et al.
Brachytherapy|June 26, 2019
An improved treatment planning and quality assurance process for Collaborative Ocular Melanoma Study eye plaque brachytherapyR A Weersink, S Patterson, H Ballantyne, et al.
Brachytherapy|October 15, 2019
Vaginal cuff brachytherapy in the adjuvant setting for patients with high-risk early-stage cervical cancerGeovanne Pedro Mauro, Rodolpho Truffa Kleine, Samantha Cabral Severino da Costa, et al.
Brachytherapy|April 12, 2019
Concurrent chemoradiation for cervical cancer: Comparison of LDR and HDR brachytherapyAlexander J Lin, Pamela Samson, Jacqueline Zoberi, et al.
Brachytherapy|September 25, 2018
Selection of patients who would not require long-term prostate-specific antigen monitoring after low-dose-rate brachytherapyNaoya Niwa, Kazuhiro Matsumoto, Toru Nishiyama, et al.
Brachytherapy|September 16, 2018
Declining brachytherapy utilization for high-risk prostate cancer-Can clinical pathways reverse the trend?Diane C Ling, Pooja Karukonda, Ryan P Smith, et al.
Brachytherapy|July 5, 2018
Low-dose-rate brachytherapy for prostate cancer in renal transplant recipientsI Rivero-Belenchón, I Osmán-García, C B Congregado-Ruíz, et al.
Brachytherapy|May 13, 2017
Dose-volume correlation of cumulative vaginal doses and late toxicity after adjuvant external radiation and brachytherapy for cervical cancerRoshni Singh, Supriya Chopra, Reena Engineer, et al.
Brachytherapy|April 27, 2017
Prostate brachytherapy, either alone or in combination with external beam radiation, is associated with longer overall survival in men with favorable pathologic Group 4 (Gleason score 8) prostate cancerMatthew W Jackson, Arya Amini, Bernard L Jones, et al.
Pageof 207